Outlook Therapeutics, Inc. OTLKW 深 滬
已收盤 02-16 16:00:00 美东时间
0.03
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.03
- 總市值 8.75万
- 52周最高 1.27
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.01
- 委 比 0.00%
- 總股本 291.70万
- 歷史最高 3.49
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.01
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Outlook gains approval for ophthalmic bevacizumab for wet AMD
The US FDA has approved Outlook Therapeutics' (OTLK) Lytenava (bevacizumab-vikg) for wet AMD. Lytevana is the first ophthalmic bevacizumab approved for the condition. It is expected to launch by the e...
07-25 03:20
Outlook Therapeutics Says FDA Approves LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration, Commonly Known As Wet AMD
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation Company Launches Commercial Franchise Positioned to Establish a New Standard as...
07-25 02:41
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Outlook Therapeutics' LYTENAVA, an FDA-approved ophthalmic bevacizumab, becomes the first specifically developed for intravitreal administration to treat wet AMD. The approval marks a significant milestone in retina care, offering a purpose-built formulation with rigorous clinical backing and manufacturing consistency. With anticipated 12 years of market exclusivity under BPCIA, LYTENAVA aims to establish a new standard in the $8.5 billion U.S. r...
07-24 18:40
Why Is Kalaris Therapeutics Stock Gaining Friday?
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced expanded data from its Phase 1a single ascending dose trial evaluating TH103 for the treatment of neovascular age-related macular degeneration. Following the announcement, the stock jumped nearly 18%. The clinical-stage biopharmaceutical company sta...
07-18 01:31
Outlook Therapeutics Shareholders Approve Major Capital Changes
The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 16, 202...
07-17 17:17
Outlook Therapeutics Regains Nasdaq Minimum Bid Compliance
The latest update is out from Outlook Therapeutics ( ($OTLK) ). On February 18,...
06-27 05:54
Outlook Therapeutics’ Resubmitted ONS-5010 BLA Accepted by FDA
Outlook Therapeutics ( ($OTLK) ) has provided an update. On June 16, 2026, Outl...
06-16 21:49
Outlook gains as wet AMD therapy reconsidered for FDA review
Outlook Therapeutics (OTLK) traded higher in the premarket on Tuesday after the U.S. Food and Drug Administration agreed to reconsider its marketing application for ONS-5010, a treatment targeting the...
06-16 21:23
Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised the price target for Chefs’ Warehouse Inc (NASDAQ:CHEF) from $82 to $100. BTIG analyst Peter Saleh...
06-11 19:49
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $6 to $10.
06-11 17:46
